These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38831322)

  • 1. Deciphering the molecular nexus of BTG2 in periodontitis and diabetic kidney disease.
    Pan B; Teng Y; Wang R; Chen D; Chen H
    BMC Med Genomics; 2024 Jun; 17(1):152. PubMed ID: 38831322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tripterygium glycoside suppresses epithelial‑to‑mesenchymal transition of diabetic kidney disease podocytes by targeting autophagy through the mTOR/Twist1 pathway.
    Tao M; Zheng D; Liang X; Wu D; Hu K; Jin J; He Q
    Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34165172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of high mobility group box 1 (HMGB1) attenuates podocyte apoptosis and epithelial-mesenchymal transition by regulating autophagy flux.
    Jin J; Gong J; Zhao L; Zhang H; He Q; Jiang X
    J Diabetes; 2019 Oct; 11(10):826-836. PubMed ID: 30864227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Krüppel‑like factor 4 ameliorates diabetic kidney disease by activating autophagy via the mTOR pathway.
    Gong J; Zhan H; Li Y; Zhang W; Jin J; He Q
    Mol Med Rep; 2019 Oct; 20(4):3240-3248. PubMed ID: 31432191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STIM promotes the epithelial-mesenchymal transition of podocytes through regulation of FcγRII activity in diabetic nephropathy.
    Jin J; Ye M; Hu K; Gong J; He Q
    Histol Histopathol; 2019 Jun; 34(6):671-682. PubMed ID: 30475382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tripterygium glycoside protects diabetic kidney disease mouse serum-induced podocyte injury by upregulating autophagy and downregulating β-arrestin-1.
    Zhan H; Jin J; Liang S; Zhao L; Gong J; He Q
    Histol Histopathol; 2019 Aug; 34(8):943-952. PubMed ID: 30839094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p66Shc regulates podocyte autophagy in high glucose environment through the Notch-PTEN-PI3K/Akt/mTOR pathway.
    Zheng D; Tao M; Liang X; Li Y; Jin J; He Q
    Histol Histopathol; 2020 Apr; 35(4):405-415. PubMed ID: 31650524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jiedu Tongluo Baoshen formula enhances podocyte autophagy and reduces proteinuria in diabetic kidney disease by inhibiting PI3K/Akt/mTOR signaling pathway.
    Jin D; Liu F; Yu M; Zhao Y; Yan G; Xue J; Sun Y; Zhao D; Li X; Qi W; Wang X
    J Ethnopharmacol; 2022 Jul; 293():115246. PubMed ID: 35398500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes.
    Chen D; Liu Y; Chen J; Lin H; Guo H; Wu Y; Xu Y; Zhou Y; Zhou W; Lu R; Zhou J; Wu J
    Eur J Pharmacol; 2021 Jul; 902():174121. PubMed ID: 33901462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement factor B in high glucose-induced podocyte injury and diabetic kidney disease.
    Lu Q; Hou Q; Cao K; Sun X; Liang Y; Gu M; Xue X; Zhao AZ; Dai C
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes.
    Lay AC; Hale LJ; Stowell-Connolly H; Pope RJP; Nair V; Ju W; Marquez E; Rollason R; Hurcombe JA; Hayes B; Roberts T; Gillam L; Allington J; Nelson RG; Kretzler M; Holly JMP; Perks CM; McArdle CA; Welsh GI; Coward RJM
    Diabetologia; 2021 Jul; 64(7):1690-1702. PubMed ID: 33758952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
    He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
    Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Down-regulation of PHLPP1 expression ameliorates high glucose-induced autophagy inhibition and apoptosis promotion of podocytes by activating PI3K/AKT/mTOR pathway].
    Cai G; Zhang J; Wang R
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jan; 37(1):8-15. PubMed ID: 33441223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paeoniflorin binds to VEGFR2 to restore autophagy and inhibit apoptosis for podocyte protection in diabetic kidney disease through PI3K-AKT signaling pathway.
    Wang X; Jiang L; Liu XQ; Huang YB; Wang AL; Zeng HX; Gao L; Zhu QJ; Xia LL; Wu YG
    Phytomedicine; 2022 Nov; 106():154400. PubMed ID: 36049428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Triptolide inhibits NLRP3 inflammasome activation and ameliorates podocyte epithelial-mesenchymal transition induced by high glucose].
    Wu W; Liu BH; Wan YG; Sun W; Liu YL; Wang WW; Fang QJ; Tu Y; Yee HY; Yuan CC; Wan ZY
    Zhongguo Zhong Yao Za Zhi; 2019 Dec; 44(24):5457-5464. PubMed ID: 32237395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Jixuepaidu Tang-1 inhibits epithelial-mesenchymal transition and alleviates renal damage in DN mice through suppressing long non-coding RNA LOC498759.
    Jin J; Zhang Z; Chen J; Liu Y; Chen Q; Wang Q
    Cell Cycle; 2019 Nov; 18(22):3125-3136. PubMed ID: 31564202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wogonin protects glomerular podocytes by targeting Bcl-2-mediated autophagy and apoptosis in diabetic kidney disease.
    Liu XQ; Jiang L; Li YY; Huang YB; Hu XR; Zhu W; Wang X; Wu YG; Meng XM; Qi XM
    Acta Pharmacol Sin; 2022 Jan; 43(1):96-110. PubMed ID: 34253875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycogen synthase kinase‑3β is required for epithelial‑mesenchymal transition and barrier dysfunction in mouse podocytes under high glucose conditions.
    Guo J; Yang L; Qiao Y; Liu Z
    Mol Med Rep; 2016 Nov; 14(5):4091-4098. PubMed ID: 27748847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podocyte programmed cell death in diabetic kidney disease: Molecular mechanisms and therapeutic prospects.
    Yang H; Sun J; Sun A; Wei Y; Xie W; Xie P; Zhang L; Zhao L; Huang Y
    Biomed Pharmacother; 2024 Aug; 177():117140. PubMed ID: 39018872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition.
    Coppola V; Musumeci M; Patrizii M; Cannistraci A; Addario A; Maugeri-Saccà M; Biffoni M; Francescangeli F; Cordenonsi M; Piccolo S; Memeo L; Pagliuca A; Muto G; Zeuner A; De Maria R; Bonci D
    Oncogene; 2013 Apr; 32(14):1843-53. PubMed ID: 22614007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.